Guidelines for the use of PET-CT scanning approved for NHS Scotland by the Scottish Clinical Imaging Network (SCIN) PET-CT working group are available below:
- PET-CT Scanning in the management of patients with Lymphoma
- PET-CT Scanning in the management of patients with Colorectal Cancer
- Clinical indications for the use of 68GALLIUM PSMA PET-CT in Prostate Cancer patients
- Clinical indications for the use of 18F-FDG PET-CT in Oesophageal & Oesophagogastric Junction Cancer
- Clinical indications for the use of 18F-FDG PET-CT in Lung Cancer in Scotland
- Clinical indications for the use of 18F-FDG PET-CT imaging in the management of Head & Neck Cancer
- Clinical indications for the use of 18F-FDG PET-CT in the management of Gynaecological Cancer
- Clinical indications for the use of 68GALLIUM DOTA PET-CT (68Ga DOTA) in Neuroendocrine Tumours
- Clinical indications for the use of 18F FDG PET-CT Imaging in Vasculitis
- Clinical indications for the use of 18F FDG PET-CT in Breast Cancer patients in Scotland
- Clinical indications for the use of 18F FDG PET-CT malignant melanoma in Scotland
- Clinical indications for the use of FDG PET-CT Imaging in the management of sarcoma patients and gastrointestinal stromal tumours
- Clinical Indications for the use of 18F FDG PET-CT in pancreatic and hepatobiliary cancer
- Clinical indications for the use of 18F FDG PET-CT for patients with brain tumours in Scotland